#1 Clinical Trials Search in Europe

Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins

This article summarizes several clinical trials investigating the use of Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins, also known as incobotulinumtoxinA or NT 201, for treating various medical conditions. The trials explore its efficacy and safety in addressing issues such as diabetic neuropathic pain, overactive bladder, spasticity, temporomandibular disorders, and incisional hernia repair. These studies aim to expand our understanding of this neurotoxin’s potential therapeutic applications beyond its well-known cosmetic uses.

Table of Contents

What is CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A?

CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS, also known as incobotulinumtoxinA or NT 201, is a purified form of botulinum toxin type A[1]. It is a neurotoxin produced by the bacterium Clostridium botulinum, but it has been refined for medical use. This particular formulation is free of complexing proteins, which means it contains only the active neurotoxin without additional bacterial proteins[1].

How does it work?

The neurotoxin works by temporarily blocking nerve signals to muscles, causing them to relax. Specifically, it prevents the release of a neurotransmitter called acetylcholine at the junction between nerves and muscles[1]. This mechanism of action makes it useful for treating various conditions characterized by muscle overactivity or spasms.

What medical conditions can it treat?

CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A is being studied for and used in the treatment of several medical conditions, including:

  • Diabetic neuropathic pain: It is being investigated for treating pain in the lower limbs caused by diabetic neuropathy[2].
  • Chronic neuropathic pain: Studies are exploring its use in treating chronic pain due to nerve damage or injury[3].
  • Overactive bladder (OAB): It’s being tested as a treatment for OAB symptoms in women[4].
  • Lower limb spasticity: The neurotoxin is used to treat muscle stiffness and spasms in the legs, particularly in patients who have had a stroke or traumatic brain injury[1].
  • Temporomandibular disorders: Research is ongoing into its effectiveness for jaw pain and dysfunction[5].
  • Incisional hernia treatment: It’s being studied as a pre-operative treatment to relax abdominal muscles before hernia repair surgery[6].

How is it administered?

The neurotoxin is typically administered through injection. The method of injection can vary depending on the condition being treated:

  • For diabetic neuropathic pain, it may be injected around nerves in the legs[2].
  • In OAB treatment, it can be injected into the bladder wall using a special delivery system[4].
  • For spasticity, it’s injected directly into the affected muscles[1].
  • In temporomandibular disorders, it may be injected into jaw muscles[5].

The dosage and frequency of administration can vary widely depending on the condition and individual patient factors. Always follow your healthcare provider’s instructions carefully.

How effective is it?

The effectiveness of CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A varies depending on the condition being treated. Clinical trials are ongoing to determine its efficacy for various uses. For example:

  • In lower limb spasticity, it has shown promise in reducing muscle stiffness and improving range of motion[1].
  • For overactive bladder, studies are investigating its potential to reduce urinary incontinence episodes and improve quality of life[4].
  • In neuropathic pain conditions, research is exploring its ability to reduce pain intensity and improve daily functioning[2][3].

What are the potential side effects?

As with any medical treatment, CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A can cause side effects. These can vary depending on the area of injection and the condition being treated. Some potential side effects include:

  • Muscle weakness near the injection site
  • Pain or bruising at the injection site
  • Headache
  • Fatigue
  • Flu-like symptoms

In rare cases, the toxin’s effects may spread beyond the injection site, potentially causing more serious side effects like difficulty swallowing or breathing. It’s crucial to report any unusual symptoms to your healthcare provider immediately[1].

Precautions and contraindications

CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A is not suitable for everyone. It should not be used in patients with:

  • Known allergies to botulinum toxin products
  • Infection at the proposed injection site
  • Certain neuromuscular disorders (e.g., myasthenia gravis)

Pregnant or breastfeeding women should consult their healthcare provider before using this treatment. Additionally, it may interact with certain medications, particularly those that affect neuromuscular function[1].

Ongoing research and future applications

Research into new applications for CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A is ongoing. Current areas of investigation include:

  • Its potential use in treating chronic migraine headaches
  • Applications in cosmetic procedures
  • Its role in managing various types of chronic pain

As research progresses, we may see this versatile neurotoxin being used to treat an even wider range of medical conditions in the future[1].

Trial Focus Condition Administration Method Key Outcomes Measured
Diabetic Neuropathic Pain Diabetic peripheral neuropathic pain Perineural injections Pain relief, sensory profiles, muscle power, quality of life
Chronic Neuropathic Pain Postherpetic neuralgia or peripheral nerve injury Subcutaneous injections Average Daily Pain intensity, Neuropathic Pain Symptom Inventory
Overactive Bladder Idiopathic overactive bladder in women Intravesical administration Safety, usability of delivery system, initial efficacy
Pediatric Lower Limb Spasticity Lower limb spasticity in children with cerebral palsy Intramuscular injections Changes in muscle tone, goal attainment, quality of life
Temporomandibular Disorders Myalgia and myofascial pain Injections in masseter and temporal muscles Pain relief, jaw function, quality of life
Incisional Hernia Treatment Large incisional hernia Preoperative injections in abdominal wall Post-operative complications, surgical outcomes
Adult Lower Limb Spasticity Spasticity after stroke or traumatic brain injury Intramuscular injections Changes in muscle tone, global impression of change, safety

FAQ

  • What medical conditions are being studied using Clostridium Botulinum Neurotoxin Type A in these clinical trials? The clinical trials are investigating the use of Clostridium Botulinum Neurotoxin Type A for various conditions including diabetic neuropathic pain, overactive bladder, lower limb spasticity in adults and children, temporomandibular disorders, and as a pre-treatment for large incisional hernia repair.
  • How is the neurotoxin administered in these trials? The administration method varies depending on the condition being treated. It includes intramuscular injections, perineural injections, subcutaneous injections, intravesical administration (into the bladder), and dental use.
  • What are some of the primary outcomes being measured in these trials? Primary outcomes include changes in pain intensity, muscle tone (spasticity), urinary incontinence episodes, quality of life measures, and treatment-related adverse events. Some trials also assess functional improvements and patient/physician-reported global impressions of change.
  • Are there any common side effects or safety concerns mentioned in these trials? While specific side effects vary by trial, common safety concerns include monitoring for adverse events related to the injection site, potential spread of toxin effects, and caution in patients with certain neuromuscular conditions. Some trials exclude patients with a history of botulinum toxin hypersensitivity or certain medical conditions.
  • What is the typical dose range of Clostridium Botulinum Neurotoxin Type A used in these trials? The dose ranges vary widely depending on the condition and area being treated. Doses mentioned in the trials range from 100 units up to 800 units for some applications. The specific dosing is carefully determined based on the treatment area and condition severity.

Ongoing Clinical Trials on Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins

  • Study of incobotulinumtoxinA injections for prevention of chronic migraine in adult patients

    Recruiting

    3 1 1
    Investigated drugs:
    Austria Czechia Denmark France Germany Italy +3

  • Study of IncobotulinumtoxinA injections compared to placebo for prevention of episodic migraine attacks

    Recruiting

    3 1 1
    Investigated drugs:
    Austria Czechia Denmark France Germany Italy +3

  • Study on Clostridium Botulinum Neurotoxin Type A for Treating Myalgia and Myofascial Pain in Patients with Temporomandibular Disorders

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Study of NT 201 compared to placebo in adults with moderate to severe platysma prominence

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    France Germany Poland Spain

  • Evaluation of Botulinum Toxin Injections for Women with Severe Primary Dysmenorrhea Unresponsive to First-Line Treatments

    Recruiting

    3 1 1
    Investigated drugs:
    France

  • Study on the Effectiveness of Clostridium Botulinum Neurotoxin Type A for Reducing Wrinkles in Adults

    Recruiting

    4 1 1
    Investigated drugs:
    The Netherlands

  • Study on Botulinum Toxin Type A for Treating Hidradenitis Suppurativa in Patients: A Comparison of Different Drug Combinations

    Recruiting

    3 1 1
    Investigated drugs:
    Denmark

  • Study on Botulinum Toxin for Patients with Degenerative Rotator Cuff Tendinopathy

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of individualized doses of botulinum toxin type A (incobotulinumtoxin) in adults with severe spasticity caused by brain damage

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Botulinum Toxin A Injection for Patients with Large Incisional Hernia

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Clostridium Botulinum Neurotoxin Type A: A purified protein neurotoxin produced by the bacterium Clostridium botulinum. It works by temporarily blocking nerve signals to muscles, causing localized muscle relaxation. In these trials, it's being studied for various therapeutic uses beyond its well-known cosmetic applications.
  • IncobotulinumtoxinA: The pharmaceutical name for a specific formulation of botulinum toxin type A that is free from complexing proteins. It's also referred to as NT 201 in some clinical trials.
  • Spasticity: A condition in which certain muscles are continuously contracted, causing stiffness or tightness that can interfere with normal movement and speech. It's often associated with conditions like cerebral palsy, multiple sclerosis, or after a stroke or brain injury.
  • Neuropathic Pain: Pain caused by damage or disease affecting the somatosensory nervous system. It's often described as burning, stabbing, or shooting pain that can be chronic and difficult to treat with conventional pain medications.
  • Overactive Bladder (OAB): A condition characterized by a frequent, sudden urge to urinate that may be difficult to control. It can lead to involuntary loss of urine (urge incontinence) and can significantly impact quality of life.
  • Temporomandibular Disorder (TMD): A group of conditions affecting the temporomandibular joint (jaw joint) and the muscles of mastication (chewing muscles). It can cause pain in the jaw, face, and neck, as well as difficulty in jaw movement.
  • Incisional Hernia: A type of hernia that occurs through a surgical incision or scar in the abdominal wall. Large incisional hernias can be challenging to repair and may benefit from pre-surgical treatments to improve outcomes.
  • Modified Ashworth Scale (MAS): A clinical measure of muscle spasticity based on assessments of resistance during passive soft-tissue stretching. It's commonly used to evaluate the effectiveness of treatments for spasticity.
  • Intravesical Administration: The delivery of medication directly into the bladder, typically through a catheter. This method is being explored for treating overactive bladder with botulinum toxin.
  • Perineural Injection: An injection of medication around a nerve or group of nerves. In some trials, this technique is being used to deliver botulinum toxin for treating neuropathic pain.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-nt-201-botulinum-toxin-for-treating-lower-limb-spasticity-in-adults-after-stroke-or-traumatic-brain-injury/
  2. http://clinicaltrials.eu/trial/study-of-incobotulinumtoxin-a-injections-for-diabetic-neuropathic-pain-in-the-lower-limbs/
  3. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-nt-201-injections-for-adults-with-chronic-neuropathic-pain-from-postherpetic-neuralgia-or-nerve-injury/
  4. http://clinicaltrials.eu/trial/study-on-overactive-bladder-treatment-for-women-using-clostridium-botulinum-neurotoxin-type-a-and-vibe-system/
  5. http://clinicaltrials.eu/trial/study-on-clostridium-botulinum-neurotoxin-type-a-for-treating-myalgia-and-myofascial-pain-in-patients-with-temporomandibular-disorders/
  6. http://clinicaltrials.eu/trial/study-on-botulinum-toxin-a-injection-for-patients-with-large-incisional-hernia/